The Board of Active Biotech AB Proposes that the Annual General Meeting Resolve to Make a Guaranteed Rights Issue of Approximately SEK 160 M

LUND, SWEDEN--(Marketwire - April 07, 2008) - Active Biotech has five projects in clinical phase, of which laquinimod and RhuDex® are managed and financed by partners. The clinical projects that are managed and financed on a proprietary basis are TASQ, 57-57 and ANYARA, all of which are proceeding according to plan. The potential value of the projects increases in pace with their advancement in clinical development, thereby continuously raising shareholder value. In 2008/09, new information and clinical data will be published relating to all three of these projects.